Comparison of furosemIde with hypertonic saline to carperitide in the treatment of acute decompensated heart failure
Not Applicable
- Conditions
- acute decompensated heart failure
- Registration Number
- JPRN-UMIN000011553
- Lead Sponsor
- CONFIRM ADHF investigation commettiee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1. Diabetes with poor control (HbA1C > 9%). 2. Critical liver dysfunction. 3. Acute coronary syndrome. 4. Acute life-threating disease. 5. HOCM. 6. Critical lung disease. 7. Pulmonary hypertension not due to heart failure. 8. Has experienced myocardial infarction, cerebral infarction, cerebral hemorahge, PCI, and open heart surgery within 3 months. 9. Needs IABP, PCPS, and CRRT. 10. Needs intibation for respiratory management. 11. Hypernatremia (148mEq/l and more) 12. can not obtein body weight 13. Critical cerebrovascular disease. 14. Has already administered inotrope, PDE III, and carperitide. 15. Considered inappropriate for the entry of the study by physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method weight reduction from the start of the study to 72 hours after the start
- Secondary Outcome Measures
Name Time Method 1. Improvement in edema at 72 hours after start of study. 2. Dyspnea at 6, 24 and 72 hours after the satrt of the study. 3. Urinary volume for 72 hours. 4. Change in renal function. 5. Earlier termination of continuous infusion therapy due to clinical improvement. 6. Need of additional dose of furosemide, inotrope, PDE III inhibitor, CRRT, assisted circulation devices, NPPV and intubation. 7. Occurrence of life-threatening arrhythmia 8. Hospitalization due to worsening heart failure and/or mortality by 30 days and 180 days